The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)

Bibliografski detalji
Glavni autori:	Lane, J, Hamdy, F, Neal, D, Donovan, J, Grp, P
Format:	Conference item
Izdano:	2004

Slični predmeti

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
od: Hamdy, F, i dr.
Izdano: (2006)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
od: Lane, J, i dr.
Izdano: (2009)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
od: Lane, J, i dr.
Izdano: (2010)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
od: J. Donovan, i dr.
Izdano: (2003-01-01)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
od: Wade, J, i dr.
Izdano: (2015)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
od: Catto, J, i dr.
Izdano: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
od: Catto, J, i dr.
Izdano: (2011)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
od: Lane, J, i dr.
Izdano: (2007)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
od: Collin, S, i dr.
Izdano: (2009)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
od: Burton, A, i dr.
Izdano: (2013)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
od: S. Sanghera, i dr.
Izdano: (2020-10-01)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
od: Donovan, J, i dr.
Izdano: (2003)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
od: Hamdy, FC, i dr.
Izdano: (2020)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
od: Neal, D, i dr.
Izdano: (2019)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
od: Freddie C Hamdy, i dr.
Izdano: (2020-08-01)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
od: Rosario, D, i dr.
Izdano: (2008)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
od: Johnston, T, i dr.
Izdano: (2016)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
od: Zuccolo, L, i dr.
Izdano: (2013)

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
od: Mills, N, i dr.
Izdano: (2003)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
od: Lane, A, i dr.
Izdano: (2016)

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
od: Hamdy, F
Izdano: (2017)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
od: Er, V, i dr.
Izdano: (2017)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
od: Rosario, D, i dr.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
od: Rosario, D, i dr.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
od: Rosario, D, i dr.
Izdano: (2012)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
od: Dimitropoulou, P, i dr.
Izdano: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
od: Dimitropoulou, P, i dr.
Izdano: (2011)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
od: Mills, N, i dr.
Izdano: (2006)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
od: Donovan, JL, i dr.
Izdano: (2017)

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
od: Chris Metcalfe, i dr.
Izdano: (2020-09-01)

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
od: Adams, Charleen D., i dr.
Izdano: (2018)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
od: Murad, A, i dr.
Izdano: (2011)

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
od: Young, GJ, i dr.
Izdano: (2020)

Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.
od: Hamdy, F, i dr.
Izdano: (2003)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
od: Hamdy, F, i dr.
Izdano: (2006)

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.
od: Murad, A, i dr.
Izdano: (2009)

Media and internet impact on randomisation rates and treatment acceptability in the protect study
od: Lane, J, i dr.
Izdano: (2008)

A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
od: Murad, A, i dr.
Izdano: (2010)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
od: Isaac Yi Kim
Izdano: (2023-07-01)

The protect (prostate testing for cancer and treatment) study: Advanced cases found through a UK screening study
od: Neal, D, i dr.
Izdano: (2006)